Relmada Therapeutics (RLMD) investor relations material

Strategic updates and program focus

• Shifted to lower-risk programs, acquiring two new assets this year to drive near-term value.

• NDB-01, an extended-release intravesical chemotherapy gel for non-muscle invasive bladder cancer, is the most advanced asset and main value driver for the next 1-2 years.

• Sopranolol, a subcutaneous injection for compulsive disorders, is being advanced for Prader-Willi syndrome with phase 2 planned for late H1 next year.

NDB-01 clinical and market positioning

• NDB-01 delivers gemcitabine and docetaxel via a gel matrix, enabling easier, faster, and safer administration in a doctor's office.

• Phase 2 open-label study shows 90% of patients cancer-free at six months, a rate described as the highest seen in this indication.

• Competing products from Johnson & Johnson and UroGen have higher costs ($120,000–$690,000/year) and logistical limitations; NDB-01 aims to be more convenient and cost-effective.

• Registration study for NDB-01 is planned to start in Q2 next year, with completion targeted for 2027.

Financial overview and capital strategy

• End of Q2 cash and equivalents totaled $20.6 million, with 33.2 million shares outstanding and an unlevered balance sheet.

• Additional financing will be needed to support clinical milestones, but not immediately; management is mindful of share price and value creation.

• Recent insider buying by CEO and Chief Medical Officer signals management confidence.